Economic Evaluation of Dapagliflozin vs. Other Oral Hypoglycemic Drugs in China via Idealized Model

Abstract

Objective: To analyze and compare economic values of cardiovascular benefits from dapagliflozin to the ones from other oral hypoglycemic drugs in China using the idealized model. Methods: An idealized model for type 2 diabetes in China with an assumed number of cases (n=2000) was established. Half of cases (Dapa group; n=1000) are treated with 10 mg of dapagliflozin and another half (Other hypoglycemic drug group; n=1000) are treated with other oral hypoglycemic drugs as monotherapy. Cardiovascular benefits resulting from the CVD-REAL study were used as the evaluation criteria for predictions of cardiovascular events. Information about the direct economic loss brought by cardiovascular events reported in relevant literatures from 20to the present (Data source including the Web of Science, PubMed, Google scholar, Wanfangdata, CNKI and Cqvip) was collected as the standard for cost calculation. Results: Compared with other oral hypoglycemic drugs, the application of dapagliflozin allows each type 2 diabetic patient to save an average of 14279.57 CNY on cardiovascular events annually in China. The annual per capita treatment cost for patients receiving dapagliflozin in the control of blood glucose and cardiovascular events was 66.98% of that of patients in the first and second-line treatment regimens, and was 65.83% of that of patients in the second-line treatment regimen. Conclusions: Based on this idealized model, dapagliflozin is expected to save 33.02% of annual cost on hyperglycemia control and cardiovascular complications in patients with type 2 diabetes compared to patients treated with the first and second-line treatment regimens and to save 34.17% of annual cost compared to patients treated with the second-line treatment regimen in China. Disclosure J. Zheng: None. L. Long: Employee; Self; AstraZeneca. Z. Ye: Employee; Self; AstraZeneca. L. Chen: None.